Key Highlights

● GNOM fell 3.15% to $64.90 in Friday's October 16 intraday session.

● GNOM tracks the Solactive Genomics Index, which caps individual holdings at 4.0%.

● The fund holds roughly 40 to 45 genomics and life sciences tools equities.

● GNOM charges a 0.50% expense ratio and reports a 30-day SEC yield of 0.00%.

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) fell 3.15% to $64.90 in intraday trading on Friday, October 16. GNOM invests across global corporations developing high-throughput automated DNA sequencing equipment, synthetic biology reagents, computational genomics software, and gene therapy protocols.

In the ongoing biotechnology revolution, market participants frequently focus on speculative clinical drug trials, where binary FDA approval decisions create extreme share price volatility. However, clinical-stage drug developers cannot discover genetic targets, design messenger RNA vaccines, or validate CRISPR guides without sophisticated physical tools. GNOM addresses this reality by targeting the essential hardware, reagents, and bioinformatics infrastructure of genomics.

Genomic infrastructure attracts long-term capital because sequencing toolmakers generate stable, recurring consumable reagent revenue across thousands of academic and commercial laboratories worldwide.

Legal Architecture & Thematic Benchmark Methodology

GNOM is registered under the Investment Company Act of 1940 as an open-end management investment company, operating as an active investment series of Global X Funds. Global X Management Company LLC, a subsidiary of Mirae Asset Global Investments, serves as the registered investment advisor. The fund launched in April 2019.

The fund tracks the Solactive Genomics Index. This rules-based benchmark screens global equities to identify companies that derive at least 50% of their revenues from genomics-related activities, including gene editing, computational genomics, sequencing equipment, and genetic diagnostics. The index applies liquidity screens and a modified market-capitalization weighting methodology that caps individual holdings at 4.0% at semi-annual reconstitutions, preventing mega-cap distortion and ensuring broad exposure across mid-cap equipment innovators. The fund invests at least 80% of its assets in exchange-listed equities positioned to benefit from advances in genomic science and biotechnology.

Portfolio Composition: Balancing Sequencing Hardware & Gene Editing

GNOM holds approximately 40 to 45 global biotechnology and life sciences tools equities. The portfolio is anchored by specialized laboratory instrument manufacturers and precision gene therapy pioneers.

Its top portfolio holdings include next-generation sequencing hardware titan Illumina (NASDAQ:ILMN), early cancer detection leader Exact Sciences, rare disease gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT), RNA interference pioneer Alnylam Pharmaceuticals (NASDAQ:ALNY), and CRISPR gene editing leaders CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA). This balanced allocation ensures that GNOM captures revenue from both clinical genetic medicines and the physical sequencing machines and flow cells required to analyze human genomes.

Cost Structure, Management Fees & Research Overhead

Global X charges an annual management expense ratio of 0.50% for GNOM. This fee covers specialized global custody, Solactive index licensing, and the multi-market trading execution required to maintain an international biotechnology portfolio.

Compared to broad healthcare index funds that charge 0.10% to 0.20%, GNOM’s 0.50% fee reflects the specialized intellectual property required to screen pure-play genomics innovators from diversified medical device manufacturers and hospital operators.

Performance Dissection: Commercial Gene Therapy Approvals

In intraday trading on Friday, October 16, GNOM opened at $67.10 and traded between $64.75 and $67.11, compared with a previous close of $67.01. The fund's 52-week range runs from $41.16 to $74.19, a recovery from multi-year biotechnology valuation troughs.

That recovery was driven by commercial inflection points: landmark regulatory approvals for ex-vivo CRISPR therapies, expanding clinical reimbursement for comprehensive genomic profiling (CGP) in oncology, and a resurgence in biopharmaceutical venture capital financing following interest rate cuts.

Distribution Profile, Dividend Yield & Form 1099 Taxation

Because genomics and life sciences tool companies reinvest virtually all operational cash flows into research and development, patent prosecution, and specialized manufacturing facilities, GNOM maintains a conservative income profile. Its 30-day SEC yield stands at 0.00%.

From a taxation standpoint, GNOM provides standard Form 1099-DIV reporting. Distributions generally qualify as qualified dividend income (QDI) for eligible US investors, and the fund completely avoids the administrative burdens of Schedule K-1 partnership tax forms.

Secondary Market Liquidity & Lead Market Making

Trading on the Nasdaq exchange under the ticker GNOM, the fund maintains active secondary market liquidity supported by institutional market makers and authorized participants. Intraday bid-ask spreads typically hover between three and six cents per share during normal market hours.

Because underlying portfolio holdings trade on deep US and European exchanges with multi-billion-dollar liquidity, authorized participants easily create and redeem shares, ensuring secondary quotes remain closely aligned with net asset value.

Primary Investment Risks: Clinical Attrition & Intellectual Property Litigation

Investing in GNOM involves significant sector risks. Clinical-stage biotechnology is characterized by high attrition rates: failure to demonstrate clinical efficacy or unexpected adverse events in clinical trials can cause individual holdings to lose substantial market value.

Additionally, the genomics tools industry is marked by aggressive intellectual property litigation over sequencing chemistry and CRISPR patent rights. Spending slowdowns by academic research institutions or pharmaceutical R&D departments also present operational headwinds.

Sequencing Tools Alongside Gene Editors

The Global X Genomics & Biotechnology ETF pairs sequencing hardware makers such as Illumina with gene editing developers including CRISPR Therapeutics and Sarepta Therapeutics.

Index eligibility requires that a company derive at least 50% of its revenues from genomics-related activities.